Medical News Today -- Researchers from Austria and Germany found that adding the bone drug zoledronic acid to endocrine therapy improved disease-free survival in premenopausal women with early stage breast cancer of the estrogen-responsive type.
Medical News Today -- Researchers from Austria and Germany found that adding the bone drug zoledronic acid to endocrine therapy improved disease-free survival in premenopausal women with early stage breast cancer of the estrogen-responsive type.
